FOR IMMEDIATE RELEASE:

Quincy Bioscience Enters the Southeastern Wisconsin Biotech Arena

RICHFIELD, Wisconsin (July 12, 2004)

Quincy Bioscience is a newly formed biotech company focused on developing new products for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. The company develops therapeutics that address the imbalance of calcium ions commonly thought to be related to the neuronal degeneration seen in such diseases of aging.

As a result of its technology, Quincy Bioscience has filed patents for both nutraceutical and pharmaceutical applications of the calcium-binding protein apoaequorin, with the intent of developing products that fight the diseases of aging. While apoaequorin is a commonly used tool in biotechnology research, to date it has not been utilized in any therapeutic manner, setting Quincy Bioscience's technology apart. Interestingly, aequorin comes from the jellyfish, an organism with one of the simplest nervous systems.

Research has shown that several (central nervous system?) conditions are related to the disruption of calcium homeostasis. Quincy Bioscience is investigating aequorin for its potential to restore the balance of that critical ion in the human body.

Based in Richfield, Wisconsin, Quincy Bioscience is division of Quincy Resource Group, and owned by local businessman Mike Beaman of West Bend, Wisconsin. Led by vice president of product development, Mark Underwood, the early stage biotech company is a member of the Wisconsin Biotech and Medical Device Association. Beaman's ownership provides the critically important phase one funding for the company's research, and backs Quincy Bioscience with valuable resources and support staff.

 For more information, contact Mark Underwood at munderwood@quincybioscience.com or toll-free at 877-677-8652.